Saturday, January 13, 2018 11:48:55 PM
Just as the government, JP Morgan, etc., suppressed Tesla's technology of free energy, anti-gravity, and the death ray, etc...
The FDA/government is suppressing our T-pill because they don't want masculine men existing. Nowadays, masculinity is considered toxic...
Antifa, doesn't want society to be patriarchal again (with men in charge again) because, they want society to continue on as being gyno-centric and to push their gender-neutral, gender-fluid and trans-gender agenda. Nowaday's, there are 71 different genders being taught in public schools and universities.
Children don't go to school to learn, they go to public school to be indoctrinated. Young boys are given dolls to play with and asked if they want to wear a skirt instead of pants. Children come home from school even more confused, before they went.
Children's books start out with a teddy bear wearing a manly bow-tie and later in the book, the bow-tie is moved up as a barrette in the hair, as boy teddy bear grows up to be a girl bear.
All hail the 3rd and 4th wave of modern feminism...LGBTQ :(
Women have all the power over men in society, in divorce court, women get child custody all the time and there are lower standards for women at work and laws that women have to be hired, even if they aren't qualified.
All it takes is a false allegation from a women and you can be fired, ruined, jailed and left destroyed. Women's false allegations aren't even prosecuted.
It's time for you to discover the true nature of women, check out MGTOW sandman on YooTube and other MGTOW channels, redonkulas for example...
Recent LPCN News
- Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 • PR Newswire (US) • 05/01/2024 12:00:00 PM
- Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity • PR Newswire (US) • 04/11/2024 11:00:00 AM
- Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis • PR Newswire (US) • 03/28/2024 12:00:00 PM
- Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154 • PR Newswire (US) • 03/25/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 10:31:06 PM
- Lipocine Announces Financial Results for the Full Year Ended December 31, 2023 • PR Newswire (US) • 03/07/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:08:06 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 11:07:26 AM
- Lipocine to Present at 36th Annual Roth Conference • PR Newswire (US) • 03/06/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 11:01:31 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 09:10:26 PM
- Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154 • PR Newswire (US) • 02/06/2024 01:00:00 PM
- Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals • PR Newswire (US) • 02/02/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 01:20:46 PM
- Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada • PR Newswire (US) • 01/18/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 03:00:12 PM
- Lipocine to Present at Biotech Showcase 2024 • PR Newswire (US) • 12/19/2023 01:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/22/2023 09:15:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 07:45:33 PM
- Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023 • PR Newswire (US) • 11/13/2023 07:45:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 06:15:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 02:50:30 PM
- Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023 • PR Newswire (US) • 11/08/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2023 01:31:11 PM
- Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023 • PR Newswire (US) • 11/01/2023 12:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM